Sandoz has yielded to the intellectual property shielding Intra-Cellular Therapies’ closely-watched schizophrenia and bipolar depression brand Caplyta (lumateperone) capsules, striking a patent-litigation settlement agreement that – for now – ensures that the antipsychotic will all but reach its ultimate patent expiry in December 2040.
Sandoz Settlement Suggests J&J Buyout Caplyta May Be Tough Nut To Crack
Six More ANDA Filers In Play But Analysts Feel IP Estate May Be Stronger Than Suspected
Sandoz is facing a lengthy wait for its proposed generic version of the touted mega blockbuster Caplyta (lumateperone), while the market waits with anticipation to see if the product’s robust IP can hold up to challenges from an additional six ANDA filers.
More from Legal & IP
• By
A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
In a precedential decision, the US Court of Appeals for the Federal Circuit has determined the meaning of the language “the patent” as it applies to patent-term extensions for reissued patents, in the context of Aurobindo’s bid to wipe out a reissued patent shielding Merck & Co’s Bridion (sugammadex) injectable.
• By
Novartis’ multi-front legal battle against MSN Laboratories over its Entresto blockbuster in the US has taken yet another twist, with a federal district court in New Jersey finding that a preliminary injunction was warranted against MSN’s product on the basis of infringement of Novartis’ trade dress.